Myotonic dystrophy type 2: theories of pathogenesis and clinical diagnostic criteria (description of two clinical cases)
https://doi.org/10.21886/2712-8156-2025-6-2-93-100
Abstract
Myotonic dystrophy type 2 is an autosomal dominant neuromuscular disease characterised by slowly progressive muscle weakness and difficulty in muscle relaxation after contraction (myotonia). The disease has a significant impact on the psychological well-being, economic status and overall quality of life of patients. Two clinical cases of myotonic dystrophy type 2 are considered. It is noted that myalgia is the main symptom reducing the quality of life.
About the Authors
N. A. Fomina-Chertousova
Rostov State Medical University
Russian Federation
Russian Federation
Neonila A. Fomina-Chertousova, Cand. Sci. (Med.), associate professor
Rostov-on-Don
A. M. Ashibokova
Rostov State Medical University
Russian Federation
Russian Federation
Aurika M. Ashibokova
Rostov-on-Don
E. S. Pivacheva
Rostov State Medical University
Russian Federation
Russian Federation
Elena S. Pivacheva
Rostov-on-Don
References
1. Marzullo M, Coni S, De Simone A, Canettieri G, Ciapponi L. Modeling Myotonic Dystrophy Type 2 Using Drosophila melanogaster. Int J Mol Sci. 2023;24(18):14182. https://doi.org/10.3390/ijms241814182
2. Liao Q, Zhang Y, He J, Huang K. Global Prevalence of Myotonic Dystrophy: An Updated Systematic Review and Meta-Analysis. Neuroepidemiology. 2022;56(3):163-173. https://doi.org/10.1159/000524734
3. Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials. 2012;33(2):302-311. https://doi.org/10.1016/j.cct.2011.11.016
4. Meola G. Myotonic dystrophy type 2: the 2020 update. Acta Myol. 2020;39(4):222-234. https://doi.org/10.36185/2532-1900-026
5. Zabnenkova V.V., Galeeva N.M., Chukhrova A.L., Rudenskaya G.E., Polyakov A.V. Myotonic dystrophies 1 and 2: fifteen years of experience of DNA diagnostics at FSBI RCMG. Medical Genetics. 2018;17(12):44-51. (In Russ.) https://doi.org/10.25557/2073-7998.2018.12.44-51
6. Wood L, Bassez G, Bleyenheuft C, Campbell C, Cossette L, Jimenez-Moreno AC, et al. Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet J Rare Dis. 2018;13(1):155. Erratum in: Orphanet J Rare Dis. 2019;14(1):199. https://doi.org/10.1186/s13023-018-0889-0
7. Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19(7):776-782. https://doi.org/10.1038/ejhg.2011.23
8. Rudenskaya G.E., Polyakov A.V. Myotonic dystrophy type 2. Annals of Clinical and Experimental Neurology. 2012;6(2):55-60. (In Russ.) eLIBRARY ID: 17789116 EDN: NMJDIX
9. Peric S, Rakocevic-Stojanovic V, Meola G. Cerebral involvement and related aspects in myotonic dystrophy type 2. Neuromuscul Disord. 2021;31(8):681-694. https://doi.org/10.1016/j.nmd.2021.06.002
10. Soltanzadeh P. Myotonic Dystrophies: A Genetic Overview. Genes (Basel). 2022;13(2):367. https://doi.org/10.3390/genes13020367
11. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108(1):260-265. https://doi.org/10.1073/pnas.1013343108
12. Zu T, Cleary JD, Liu Y, Bañez-Coronel M, Bubenik JL, Ayhan F, et al. RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. Neuron. 2017;95(6):1292-1305.e5. https://doi.org/10.1016/j.neuron.2017.08.039
13. Cleary JD, Pattamatta A, Ranum LPW. Repeat-associated non-ATG (RAN) translation. J Biol Chem. 2018;293(42):16127-16141. https://doi.org/10.1074/jbc.R118.003237
14. Czubak K, Taylor K, Piasecka A, Sobczak K, Kozlowska K, Philips A, et al. Global Increase in Circular RNA Levels in Myotonic Dystrophy. Front Genet. 2019;10:649. https://doi.org/10.3389/fgene.2019.00649
15. Chen W, Wang Y, Abe Y, Cheney L, Udd B, Li YP. Haploinsuffciency for Znf9 in Znf9+/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol. 2007;368(1):8-17. https://doi.org/10.1016/j.jmb.2007.01.088
16. Ursu SF, Alekov A, Mao NH, Jurkat-Rott K. ClC1 chloride channel in myotonic dystrophy type 2 and ClC1 splicing in vitro. Acta Myol. 2012;31(2):144-153. PMID: 23097607; PMCID: PMC3476861.
17. Cardani R, Giagnacovo M, Botta A, Rinaldi F, Morgante A, Udd B, et al. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol. 2012;259(10):2090-2099. https://doi.org/10.1007/s00415-012-6462-1
18. Bugiardini E, Rivolta I, Binda A, Soriano Caminero A, Cirillo F, Cinti A, et al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord. 2015;25(4):301-307. https://doi.org/10.1016/j.nmd.2015.01.006
19. Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol. 2017;264(12):2472-2480. https://doi.org/10.1007/s00415-017-8653-2
20. Papadopoulos C, Kekou K, Xirou S, Kitsiou-Tzeli S, Kararizou E, Papadimas GK. Early onset posterior subscapular cataract in a series of myotonic dystrophy type 2 patients. Eye (Lond). 2018;32(3):622-625. https://doi.org/10.1038/eye.2017.280
21. Montagnese F. Current Treatment Options for Patients with Myotonic Dystrophy Type 2. Curr Treat Options Neurol. 2021;23:31. https://doi.org/10.1007/s11940-021-00686-0
22. Schoser B, Montagnese F, Bassez G, Fossati B, Gamez J, Heatwole C, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract. 2019;9(4):343-353. https://doi.org/10.1212/CPJ.0000000000000645
23. Minnerop M, Luders E, Specht K, Ruhlmann J, Schneider-Gold C, Schröder R, et al. Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2. J Neurol. 2008;255(12):1904-1909. https://doi.org/10.1007/s00415-008-0997-1
24. van Vliet J, Tieleman AA, van Engelen BGM, Bassez G, Servais L, Béhin A, et al. Hearing impairment in patients with myotonic dystrophy type 2. Neurology. 2018a;90:e615-22. https://doi.org/10.1212/WNL.0000000000004963
25. Romigi A, Maestri M, Nicoletta C, Vitrani G, Caccamo M, Siciliano G, et al. Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2. Curr Neurol Neurosci Rep. 2019;19(2):9. https://doi.org/10.1007/s11910-019-0924-0
26. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657-664. https://doi.org/10.1212/01.wnl.0000054481.84978.f9
Review
For citations:
Fomina-Chertousova N.A., Ashibokova A.M., Pivacheva E.S. Myotonic dystrophy type 2: theories of pathogenesis and clinical diagnostic criteria (description of two clinical cases). South Russian Journal of Therapeutic Practice. 2025;6(2):93-100. (In Russ.) https://doi.org/10.21886/2712-8156-2025-6-2-93-100
Views:
89
Email this article 